Author(s): Sneha Pervin, Somsubhra Ghosh, Sankhadip Bose, Nandan Sarkar

Email(s): somsubhraghosh@gmail.com

DOI: 10.52711/0974-360X.2021.00783   

Address: Sneha Pervin1, Somsubhra Ghosh1*, Sankhadip Bose2, Nandan Sarkar3
1School of Pharmacy, Techno India University, Salt Lake City, EM- 4, Sector - V, Kolkata, West Bengal, India.
2Bengal School of Technology, Sugandha, Chinsura, W. B., India.
3School of Pharmaceutical Technology, Adamas University, Barasat, Kolkata., India.
*Corresponding Author

Published In:   Volume - 14,      Issue - 8,     Year - 2021


ABSTRACT:
Primary immunodeficiency disorder (PID) refers to a heterogeneous cluster of over 350 syndromes that upshot from defects in the immune system development or function. PIDs are broadly classified as disorders of adaptive immunity or innate immunity. The enhanced efficacy of human immune serum globulin 10% with recombinant human Hyaluronidase with comparison to blood vessel human gamma globulin is a very prospective open-label study for PID. Treatment of primary immunological disorder diseases (PIDD) with Subcutaneous(SC) infusions of immune gamma globulin headed by an injection of hyazyme to extend SC tissue porousness was evaluated in two consecutive, prospective, non-controlled, multi-center studies. HYQVIA could be a subcutaneously mediated medication to treat the primary immunological disorder in adults. ENHANZE® drug delivery technology relies on the proprietary rHuPH20 macromolecule that facilitates the SC delivery of co administered medical specialty. Recombinant Human Hyaluronidase works by degrading the glycosaminoglycan hyaluronan, which plays a role in resistance to excessive flow of fluid within the Subcutaneous matrix, limiting massive volume SC drug delivery, dispersion, and absorption. Co-administration of recombinant Hyazyme with partner therapies can overcome administration time and volume barriers associated with existing SC therapeutic formulations.


Cite this article:
Sneha Pervin, Somsubhra Ghosh, Sankhadip Bose, Nandan Sarkar. Human immune globulin 10% with recombinant human Hyaluronidase- A Review. Research Journal of Pharmacy and Technology. 2021; 14(8):4504-8. doi: 10.52711/0974-360X.2021.00783

Cite(Electronic):
Sneha Pervin, Somsubhra Ghosh, Sankhadip Bose, Nandan Sarkar. Human immune globulin 10% with recombinant human Hyaluronidase- A Review. Research Journal of Pharmacy and Technology. 2021; 14(8):4504-8. doi: 10.52711/0974-360X.2021.00783   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-89


REFERENCES:
1.    Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency. N Engl J Med. 2014; 371(5): 434-46.
2.    Odek C, Kendirli T, Dogu F, et al. Patients with primary immunodeficiencies in pediatric intensive care unit: outcomes and mortality-related risk factors. J Clin Immunol. 2014; 34(3): 309-15.
3.    Sperlich JM, Grimbacher B, Workman S, Haque T, Seneviratne SL, Burns SO, et al. Respiratory infections and antibiotic usage in common variable immunodeficiency. J Allergy Clin Immunol Pract. 2018; 6:159-168. doi: 10.1016/j.jaip.2017.05.024.
4.    Compagno N, Malipiero G, Cinetto F, Agostini C, Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia. Front Immunol. 2014; 5: 626.
5.    Picard C, Al-Herz W, Bousfiha A etal. Primary immunodeficiency diseases. An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. J. Clin. Immunol. 2015; 35(8): 696-726.
6.    Available at: https://www.fda.gov/media/89844/download, accessed on 12/05/2019.
7.    Available at: http://wayback.archiveit.org/7993/20170723025727/ https:/www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm414148.htm. accessed on 12/05/2109.
8.    Available at: https://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM414440.pdf. accessed on 12/05/2019.
9.    Available at: https://www.halozyme.com/investors/news-releases/ news-release-details/2018/FDA-Accepts-Biologics-License-Application-For- Subcutaneous-Formulation-Of-Herceptin/ default.aspx. accessed on 20/05/2019.
10.    Available at: http://files.shareholder.com/downloads/ALXN/ 6264479688x0x966094/4E5A51B2-4A6E-4C45-83C1-1F8B8373B8C0/ALXN_News_2017_12_7_General.pdf. accessed on 20/05/2019
11.    Stecco, Carla; Fede, Caterina; Macchi, Veronica; Porzionato, Andrea; Petrelli, Lucia; Biz, Carlo; Stern, Robert; De Caro, Raffaele. "The fasciacytes: A new cell devoted to fascial gliding regulation". Clinical Anatomy. 31(5): 667-676. doi: 10.1002/ ca.23072.
12.    Matou NS, Gaffney J, Kumar S, Slevin M. "Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin". Int. J. Oncol. 2009; 35 (4): 761-773. doi: 10.3892/ijo_00000389.
13.    https://www.hyqvia.com/what-is-primary-immunodeficiency.
14.    Timothy Gower. "Hyaluronic acid injections for osteoarthritis". US Arthritis Foundation. Retrieved 16 March 2019.
15.    Frost GI: Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007; 4(4): 427-40.
16.    Available at: https://ncit.nci.nih.gov/ncitbrowser/pages/concept_ details.jsf;jsessionid=13BF82A11A6966263E21686F356CE488.
17.    Klocker. J, Sabitzer. H, Raunik. W, Wieser, S, Schumer. J. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett. 1998; 131:113-115.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available